P-glycoprotein and surfactants: Effect on intestinal talinolol absorption
Open accessThe DOI matches its Crossref record.
Abstract
BACKGROUND AND OBJECTIVE: Surfactants used in pharmaceutical formulations can modulate drug absorption by multiple mechanisms including inhibition of intestinal P-glycoprotein (P-gp). Our objective was to analyze the effect of 2 surfactants with different affinity for P-gp in vitro on the intestinal absorption and bioavailability of the P-gp substrate talinolol in humans. METHODS: In vitro, the influence of surfactants on talinolol permeability was studied in Caco-2 cells. In vivo, an open-label 3-way crossover study with 9 healthy male volunteers was performed. Subjects were intubated with a 1-lumen nasogastrointestinal tube. The study solution, containing either talinolol (50 mg), talinolol and D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS) (0.04%), or talinolol and Poloxamer 188 (0.8%), was administered through the tube. RESULTS: TPGS, but not Poloxamer 188, inhibited the P-gp-mediated talinolol transport in Caco-2 cells. In healthy volunteers TPGS increased the area under the plasma concentration-time curve with extrapolation to infinity (AUC 0-infinity ) of talinolol by 39% (90% confidence interval, 1.10-1.75) and the maximum plasma concentration (C max) by 100% (90% confidence interval, 1.39-2.88). Poloxamer 188 did not significantly alter the AUC 0-infinity or C max of talinolol. CONCLUSIONS: This in vivo intraduodenal perfusion study showed that low concentrations of TPGS, close to the concentrations that showed P-gp inhibition in vitro, significantly increased the bioavailability of talinolol. The study design excluded modulation of solubility by TPGS and unspecific surfactant-related effects. The latter was supported by the absence of modulation of the talinolol pharmacokinetics by Poloxamer 188, which does not modulate P-gp. Therefore we consider intestinal P-gp inhibition by TPGS as the major underlying mechanism for the increase in talinolol bioavailability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Lipids and Lipid-Based Formulations: Optimizing the Oral Delivery of Lipophilic Drugs
Porter, C. J. H., Trevaskis, N. L., & Charman, W. N. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2197 · Cited by 1,824
“One exception is a recent study that described an inhibitory effect of tocopheryl polyethylene glycol 1,000 succinate (TPGS) on the efflux of talinolol by P-gp in vitro and subsequently showed an enhancement in the oral bioavailability of talinolol in human”
BackgroundStrategies to Address Low Drug Solubility in Discovery and Development
Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005660 · Cited by 1,570
Enhancing intestinal drug solubilisation using lipid-based delivery systems
Porter, C. J. H., Pouton, C. W., Cuine, J. F., & Charman, W. N. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.10.014 · Cited by 690
The applications of Vitamin E TPGS in drug delivery
Guo, Y., Luo, J., Tan, S., Otieno, B. O., & Zhang, Z. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.02.006 · Cited by 523
Bridging solubility between drug discovery and development
Di, L., Fish, P. V., & Mano, T. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.11.007 · Cited by 491
Expression and function of efflux drug transporters in the intestine
Takano, M., Yumoto, R., & Murakami, T. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.06.005 · Cited by 356
Nanomedicinal Strategies to Treat Multidrug-Resistant Tumors: Current Progress
Dong, X., & Mumper, R. J. (2010) · Nanomedicine · doi:10.2217/nnm.10.35 · Cited by 317
Feng, S.-S., Mei, L., Anitha, P., Gan, C. W., & Zhou, W. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.02.045 · Cited by 306
Targeted delivery of paclitaxel using folate-decorated poly(lactide)-vitamin E TPGS nanoparticles
Pan, J., & Feng, S.-S. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.02.020 · Cited by 187
Cao, N., & Feng, S.-S. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.05.016 · Cited by 179
“Some reports demonstrated that TPGS can increase the oral bioavailability of cyclosporine A, vancomycin hydrochloride and talinolol in animals [23,24].”
BackgroundSex-specific effects of excipients on oral drug bioavailability
Mai, Y., Madla, C. M., Shao, H., Qin, Y., Merchant, H. A., Murdan, S., & Basit, A. W. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122365 · Cited by 13
“Although 0.8% Poloxamer 188 was reported to not inhibit intestinal P-gp for the transport of tali-nolol on male volunteers (Bogman et al., 2005), a significant (p 0.05) difference was later identified in the transport of P-gp substrate diltiazem from the intestinal sacs of male rats, pre-treated…”
Influential
Metadata
- Authors
- BOGMAN, K., ZYSSET, Y., DEGEN, L., HOPFGARTNER, G., GUTMANN, H., ALSENZ, J., & DREWE, J.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2005-01
- Volume
- 77
- Issue
- 1
- Pages
- 24-32
- ISSN
- 0009-9236 (ISSN-L)
- OpenAlex
- W2022885537
- Cited by
- 126
- References
- 0
- FWCI
- 5.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.